10x Genomics 경영진
경영진 기준 점검 4/4
10x Genomics CEO는 Serge Saxonov, Jul2012 에 임명되었습니다 의 임기는 14.08 년입니다. 총 연간 보상은 $6.33M, 10.7% 급여 및 89.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $257.14M 가치에 해당하는 회사 주식의 3.17% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.6 년과 7.2 년입니다.
핵심 정보
Serge Saxonov
최고경영자
US$6.3m
총 보수
| CEO 급여 비율 | 10.65% |
| CEO 재임 기간 | 14.1yrs |
| CEO 지분 보유율 | 3.2% |
| 경영진 평균 재임 기간 | 2.6yrs |
| 이사회 평균 재임 기간 | 7.2yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Aug 20
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)
Summary Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG’s valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution. Read the full article on Seeking Alpha분석 기사 • Aug 12
US$49.54 - That's What Analysts Think 10x Genomics, Inc. (NASDAQ:TXG) Is Worth After These Results
A week ago, 10x Genomics, Inc. ( NASDAQ:TXG ) came out with a strong set of quarterly numbers that could potentially...
내러티브 업데이트 • Aug 06
TXG: Elevated 2027 Expectations And Product Transitions Will Pressure Near Term Setup
Analyst price targets for 10x Genomics have moved sharply higher, with the fair value estimate rising from about $20.14 to $41.54 as analysts factor in higher sector multiples, expectations around single cell demand, and potential contribution from the Atera platform in coming years. Analyst Commentary Recent research on 10x Genomics shows a cluster of higher price targets, but with mixed views on how much upside is left relative to execution risk and current valuation levels.
내러티브 업데이트 • Jul 23
TXG: Cancer Collaboration And Tools Strength Will Support Balanced Outlook
The analyst price target for 10x Genomics has been raised from $45.00 to $50.00. Analysts generally point to higher sector multiples, expectations that single cell and the Atera platform could support future demand, and updated earnings models ahead of upcoming results as key reasons for the change.내러티브 업데이트 • Jul 09
TXG: Cancer Collaboration And Spatial Rollout Will Support More Constructive Outlook
Analysts have lifted the 10x Genomics fair value estimate from $40.00 to $45.00, reflecting higher Street price targets, including recent moves to $37 at Morgan Stanley, $40 at Barclays, and $45 at Citi. These changes are supported by updated earnings models and growing interest in life science tools.내러티브 업데이트 • Jun 25
TXG: Multiomic Cancer Collaboration And Spatial Launch Plans Will Support Bullish Outlook
Analysts have lifted the 10x Genomics fair value estimate to $40 from $32, reflecting a higher Street price target and modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions in recent research updates across the tools sector. Analyst Commentary Recent research on 10x Genomics reflects a cluster of bullish adjustments to price targets and ratings across the life science tools space, with several bullish analysts flagging the stock as a relative bright spot within healthcare tools and diagnostics.내러티브 업데이트 • Jun 11
TXG: Multiomic Expansion And Spatial Launch Plans Will Shape Fairly Valued Outlook
Analysts have lifted their price targets on 10x Genomics by a range of $2 to $10, reflecting updated views on the stock. These revisions are now feeding into this valuation narrative and refined assumptions around discount rate, revenue growth, profit margins, and future P/E.내러티브 업데이트 • May 28
TXG: Spatial Consumables And Spatial Partnerships Will Support Atera-Led Upside In 2026
Analysts have lifted their price targets on 10x Genomics by single digit dollar amounts, citing more constructive views on revenue growth, margins and the competitive setup. This feeds into a refreshed valuation framework even as the internal fair value estimate stays at $32.00 per share.분석 기사 • May 13
Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results
10x Genomics, Inc. ( NASDAQ:TXG ) just released its latest quarterly results and things are looking bullish. Revenues...
내러티브 업데이트 • May 12
TXG: 2026 Academic Demand Weakness Will Challenge Elevated Expectations
Analysts have raised 10x Genomics' consolidated price target by several dollars into the mid $20s, citing improving expectations for revenue growth, modestly higher profit margins, and recent research that points to steady new product adoption and a more favorable competitive environment. Analyst Commentary Recent Street research on 10x Genomics has largely centered on a series of price target revisions tied to product adoption trends, funding visibility and the mix between instruments and consumables.내러티브 업데이트 • Apr 21
TXG: Spatial Consumables Strength Will Offset Instrument Softness In 2026
The analyst price target for 10x Genomics has shifted from about $24 to $32, with analysts pointing to recent target hikes across multiple firms that reflect updated views on product adoption, competitive positioning in single cell, and mixed trends across instrument and consumables demand. Analyst Commentary Recent research shows a cluster of bullish analysts increasing their price targets on 10x Genomics, as well as at least one upgrade, pointing to a more constructive stance on the story.내러티브 업데이트 • Apr 06
TXG: Spatial Consumables And New Product Uptake Will Shape 2026 Outlook
Analysts have raised their average price target on 10x Genomics from about $18 to roughly $24, citing solid new product adoption, a favorable competitive setup in single cell, and expectations that pressure in instruments and single cell consumables could be partly offset by growth in spatial consumables. Analyst Commentary Recent research updates show a cluster of bullish analysts lifting price targets on 10x Genomics, with new targets cited at about $18, $20 and $25.내러티브 업데이트 • Mar 23
TXG: New Product Uptake And Funding Uncertainty Will Shape 2026 Setup
Analysts have nudged the blended price target for 10x Genomics higher, with recent moves such as Stifel lifting its target to $25 from $20 and UBS taking its target to $20 from $14, citing solid new product adoption, a favorable single cell competitive setup, and mixed but evolving trends in academic funding, instruments, and consumables. Analyst Commentary Recent research points to a more balanced view on 10x Genomics, with higher price targets reflecting confidence in certain growth drivers alongside caution around funding visibility and product mix.내러티브 업데이트 • Mar 07
TXG: 2026 Academic Weakness And Pricing Pressure Will Test Elevated Expectations
Analysts have inched up their price targets on 10x Genomics, with moves such as $14 to $20 at UBS, $15 to $18 at TD Cowen and $20 to $25 at Stifel. These changes reflect a mix of confidence in new product adoption, a favorable single cell competitive setup, and expectations that spatial consumables can help offset pressure in single cell consumables and softer academic instrument demand.내러티브 업데이트 • Feb 21
TXG: 2026 Academic Demand And Pricing Pressures Will Challenge Rich Sentiment
The analyst price target for 10x Genomics has increased from $14 to $17, as analysts factor in updated assumptions for faster revenue growth, slightly higher margins, and a higher future P/E multiple, despite ongoing caution around academic demand and single cell consumables. Analyst Commentary Recent street research on 10x Genomics points to a mixed setup, with price target changes reflecting both interest in the story and clear caution around execution, product mix, and end market trends.내러티브 업데이트 • Feb 07
TXG: Higher Q4 Bar And Soft 2026 Setup May Cap Upside
Analysts have nudged their price target on 10x Genomics up to $18 from $15, citing updated assumptions on discount rate, revenue growth, profit margin and future P/E that they view as better aligned with their latest outlook on the life science tools space. Analyst Commentary Recent research points to a more balanced stance on 10x Genomics, with the higher price target reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E while the rating remains neutral.분석 기사 • Jan 24
10x Genomics, Inc. (NASDAQ:TXG) Stock Rockets 34% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, 10x Genomics, Inc. ( NASDAQ:TXG ) shares have been powering on, with a gain of 34% in...내러티브 업데이트 • Jan 23
TXG: ARK Buying And Soft 2026 Outlook Will Restrain Upside Potential
Analysts have nudged their 10x Genomics price target higher to about $18, up from around $17.36. This reflects slightly updated fair value, discount rate, revenue growth, profit margin, and future P/E assumptions, alongside recent Street research that includes an $18 target and continued institutional interest.내러티브 업데이트 • Jan 08
TXG: Q4 Guidance And 2026 Outlook Will Likely Pressure Rich Sentiment
Analysts have raised their fair value estimate for 10x Genomics from US$9.00 to US$14.00, citing higher assumed revenue growth, a richer future P/E multiple, and recent Street research that highlights an increased price target in the life science tools space. Analyst Commentary Recent research in the life science tools space has highlighted a cautious tone around near term expectations for 10x Genomics, even as some price targets have been adjusted.내러티브 업데이트 • Dec 25
TXG: ARK Buying And Platform Advances Will Shape Future Risk Reward Balance
Analysts have raised their price target on 10x Genomics by about 5 percent to reflect a modestly higher fair value estimate of approximately 17.36 dollars per share. This change is supported by slightly improved long term margin expectations and renewed institutional buying interest highlighted by recent ARK Investment purchases.내러티브 업데이트 • Dec 11
TXG: ARK Buying And Product Advances Will Shape Balanced Risk Reward Outlook
Analysts have nudged their price target for 10x Genomics slightly higher, from approximately 16.36 dollars to 16.57 dollars, citing incremental improvements in long term growth assumptions and renewed institutional interest following sizable recent share purchases. Analyst Commentary Analyst reaction to the latest moves in 10x Genomics stock has been mixed, with many highlighting both the opportunities created by recent institutional buying and the ongoing execution risks that could affect the company’s valuation trajectory.내러티브 업데이트 • Nov 27
TXG: ARK Share Purchase Will Not Offset Persistent Market Pressure
Analysts have modestly raised their fair value estimate for 10x Genomics from $15.86 to $16.36 per share. This change reflects expectations of improved revenue growth, a resilient market position, and support from recent institutional investment activity, despite ongoing macroeconomic headwinds.분석 기사 • Nov 14
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump
10x Genomics, Inc. ( NASDAQ:TXG ) shareholders would be excited to see that the share price has had a great month...내러티브 업데이트 • Nov 09
TXG: Institutional Interest And New Assay Expected To Influence Future Performance
Analysts have increased their price target for 10x Genomics from $15.08 to $15.86 per share. They cite improvements in revenue growth and profit margin as key factors behind the upward revision.내러티브 업데이트 • Aug 08
Advanced Genomics Tools Will Shape Future Precision Medicine
Despite a decline in consensus revenue growth forecasts, a rising future P/E suggests increased optimism for profitability or valuation, leading to a higher analyst price target for 10x Genomics. What's in the News 10x Genomics guided Q3 2025 revenue to $140–$144 million, noting an impact from $4.0 million in China customer purchases pulled forward due to anticipated tariff changes.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$75m |
| Mar 31 2026 | n/a | n/a | -US$23m |
| Dec 31 2025 | US$6m | US$674k | -US$44m |
| Sep 30 2025 | n/a | n/a | -US$76m |
| Jun 30 2025 | n/a | n/a | -US$85m |
| Mar 31 2025 | n/a | n/a | -US$157m |
| Dec 31 2024 | US$8m | US$625k | -US$183m |
| Sep 30 2024 | n/a | n/a | -US$183m |
| Jun 30 2024 | n/a | n/a | -US$240m |
| Mar 31 2024 | n/a | n/a | -US$264m |
| Dec 31 2023 | US$8m | US$545k | -US$255m |
| Sep 30 2023 | n/a | n/a | -US$223m |
| Jun 30 2023 | n/a | n/a | -US$172m |
| Mar 31 2023 | n/a | n/a | -US$174m |
| Dec 31 2022 | US$19m | US$504k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$167m |
| Jun 30 2022 | n/a | n/a | -US$142m |
| Mar 31 2022 | n/a | n/a | -US$89m |
| Dec 31 2021 | US$12m | US$430k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$455m |
| Jun 30 2021 | n/a | n/a | -US$504m |
| Mar 31 2021 | n/a | n/a | -US$533m |
| Dec 31 2020 | US$11m | US$400k | -US$543m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$2m | US$394k | -US$31m |
보상 대 시장: Serge의 총 보수(USD6.33M)는 US 시장에서 비슷한 규모 기업의 평균(USD8.29M) 수준입니다.
보상과 수익: Serge의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Serge Saxonov (49 yo)
14.1yrs
재임 기간
US$6,329,244
보수
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 14.1yrs | US$6.33m | 3.17% $ 257.1m | |
| Co-Founder | 14.1yrs | US$2.60m | 2.54% $ 205.9m | |
| CFO, Treasurer | 2yrs | US$2.23m | 0.070% $ 5.6m | |
| Chief of Global Operations | 2.6yrs | 데이터 없음 | 데이터 없음 | |
| Founding Scientist & CTO | 4.6yrs | 데이터 없음 | 데이터 없음 | |
| Manager of Investor Relations & Strategic Finance | no data | 데이터 없음 | 데이터 없음 | |
| General Counsel and Secretary | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Commercial Officer | 2yrs | 데이터 없음 | 데이터 없음 | |
| Associate Director of Product Management | no data | 데이터 없음 | 데이터 없음 |
2.6yrs
평균 재임 기간
51yo
평균 나이
경험이 풍부한 관리: TXG의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.6 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Co-Founder | 14.1yrs | US$6.33m | 3.17% $ 257.1m | |
| Co-Founder | 14.1yrs | US$2.60m | 2.54% $ 205.9m | |
| Independent Director | 6.4yrs | US$216.32k | 0.022% $ 1.8m | |
| Independent Chairman | 13yrs | US$283.41k | 1.88% $ 152.1m | |
| Independent Director | 7yrs | US$210.99k | 0.018% $ 1.4m | |
| Independent Director | 2.2yrs | US$208.27k | 0.052% $ 4.2m | |
| Independent Director | 7.3yrs | US$223.32k | 0.046% $ 3.7m | |
| Independent Director | 2.1yrs | US$198.32k | 데이터 없음 |
7.2yrs
평균 재임 기간
52.5yo
평균 나이
경험이 풍부한 이사회: TXG의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.2 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/20 14:04 |
| 종가 | 2026/08/20 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
10x Genomics, Inc.는 23명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |
| Kyle Mikson | Canaccord Genuity |